Those who have served in the military are about twice as likely to develop ALS as those who have not served.2,3
Enroll in the ALS Care Locator
MEDICAL PRACTICERADICAVA ORS® recognized as a MAJOR CONTRIBUTION TO PATIENT CARE by the FDA.1 Request a rep visit.
Daniel, an Air Force Veteran with ALS.
Those who have served in the military are about twice as likely to develop ALS as those who have not served.2,3
Recognizes ALS as a service-connected disease and provide medical and financial support to those with at least 90 continuous days of military service4,5,a (see footnote)
Provides resources, education, and support to caregivers of veterans6
Provides access to treatment for ALS, including RADICAVA ORS®1
Offers some benefits to a veteran's spouse or children, even if the veteran has passed away due to ALS5
Eligibility requirements may apply. Veterans should always contact their local VA for more information and any questions regarding their benefits coverage.
For unknown reasons, military veterans are more likely to be diagnosed with ALS than the general public. The addition of RADICAVA ORS® to the VA National Formulary symbolizes not only the dedication and recognition of veterans by MTPA and the VA, but also a significant step forward for those in the ALS community in need of an alternate treatment option.
Disability compensation benefits are based on disability rating and dependent family members.9
Eligibility requirements may apply. Veterans should always contact their local VA for more information and any questions regarding their benefits coverage.
They can check with their local VHA enrollment center or military treatment facility DEERS office for more information.
My patient is not currently enrolled in the VHA healthcare system and they may still qualify for ALS treatment through the VHA.14
To get started with the VHA, they can apply14:
ONLINE at VA.gov
BY CALLING 1-877-222-VETS (1-877-222-8387)
IN PERSON at their local VA medical facility
Eligibility requirements may apply. Veterans should always contact their local VA for more information and any questions regarding their benefits coverage.
If the veteran is separating from service due to a service-connected illness,
they may be eligible for VA healthcare benefits and certain TRICARE benefits.15
Please contact your Mitsubishi Tanabe Pharma America Manager of Patient Access or Federal Account Manager for more information.
aA service connection for ALS for any veteran who develops the disease at any time after separation from service4. Return to content
bBased on RADICAVA ORS® prescriptions submitted in the US as of May 2024. Not independently verified. Return to content
cData on file. Jersey City, NJ: Mitsubishi Tanabe Pharma America, Inc. Based upon data through May 31, 2024. Return to content
dFor illustrative purposes only. Return to content
DEERS=Defense Enrollment Eligibility Reporting System; MTF=Military Treatment Facility; VA=Veterans Affairs; VHA=Veterans Health Administration.
References: 1. US Department of Veterans Affairs. Pharmacy benefits management services. Accessed October 12, 2020. https://www.pbm.va.gov/apps/VANationalFormulary/
2. VA improves quality of care for veterans diagnosed with ALS. News release. US Department of Veterans Affairs. October 13, 2021. Accessed October 25, 2022. https://www.va.gov/opa/pressrel/pressrelease.cfm?id=5727 3. US Department of Veterans Affairs. Quality of care: ALS disease awareness month. Accessed October 12, 2020. https://www.va.gov/QUALITYOFCARE/education/ALS_Disease_Awareness_Month.asp 4. US Department of Veterans Affairs. ALS awareness month. Accessed September 20, 2024. https://www.va.gov/marion-health-care/stories/als-awareness-month 5. US Department of Veterans Affairs. Federal benefits for veterans, dependents, survivors, and caregivers. 2025; VA Pamphlet 80-25-1. Accessed April 2, 2025. https://department.va.gov/wp-content/uploads/2024/12/2025-Federal-Benefits-for-Veterans-Dependents-and-Survivors.pdf 6. US Department of Veterans Affairs. VA caregiver support program. Accessed September 25, 2024. https://www.caregiver.va.gov/Care_Caregivers.asp 7. Data on file. Jersey City, NJ: Mitsubishi Tanabe Pharma America, Inc. 8. US Department of Veterans Affairs. VA makes specially adaptive housing grant eligibility automatic for veterans and servicemembers living with ALS [news release]. Published March 19, 2014. Accessed September 20, 2024. https://www.va.gov/opa/pressrel/pressrelease.cfm?id=2530 9. US Department of Veterans Affairs. Current veterans disability compensation rates. Accessed September 20, 2024. https://www. va.gov/disability/compensation-rates/veteran-rates 10. US Department of Veterans Affairs. Dependency and indemnity compensation. Updated May, 2022. Accessed September 20, 2024. https://benefits.va.gov/BENEFITS/factsheets/survivors/dic.pdf 11. US Department of Veterans Affairs. Special claims. Accessed September 20, 2024. https://www.va.gov/disability/eligibility/special-claims 12. US Department of Veterans Affairs. Automobile allowance and adaptive equipment. Accessed September 20, 2024. https://www.va.gov/disability/eligibility/special-claims/automobile-allowance-adaptive-equipment 13. US Department of Veterans Affairs. VHA Handbook 1101.07: Amyotropic (sic) Lateral Sclerosis (ALS) System of Care Procedures. Published July 7, 2014. Accessed October 12, 2020. https://www.va.gov/vhapublications/ViewPublication.asp?pub_ID=3014 14. US Department of Veterans Affairs. How to apply for VA health care. Accessed October 12, 2020. https://www.va.gov/health-care/how-to-apply/ 15. US Department of Veterans Affairs. Eligibility for VA health care. Accessed October 12, 2020. https://www.va.gov/health-care/eligibility/
RADICAVA ORS® (edaravone) is contraindicated in patients with a history of hypersensitivity to edaravone or any of the inactive ingredients of this product. Hypersensitivity reactions (redness, wheals, and erythema multiforme) and cases of anaphylaxis (urticaria, decreased blood pressure, and dyspnea) have occurred.
Patients should be monitored carefully for hypersensitivity reactions. If hypersensitivity reactions occur, discontinue RADICAVA ORS, treat per standard of care, and monitor until the condition resolves.
RADICAVA ORS contains sodium bisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown but occurs more frequently in asthmatic people.
The most common adverse reactions (≥10%) reported in RADICAVA® (edaravone)-treated patients and at least 2% more frequently than placebo were contusion (15% vs 9%), gait disturbance (13% vs 9%), and headache (10% vs 6%), respectively. In an open label study, fatigue was also observed in 7.6% of patients receiving RADICAVA ORS.
Based on animal data, RADICAVA ORS may cause fetal harm.
To report suspected adverse reactions or product complaints, contact Mitsubishi Tanabe Pharma America, Inc., at 1-888-292-0058. You may also report suspected adverse reactions to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
RADICAVA ORS® (edaravone) is indicated for the treatment of amyotrophic lateral sclerosis (ALS).
Please see full Prescribing Information also available www.radicavaors.com.
RADICAVA ORS® (edaravone) is contraindicated in patients with a history of hypersensitivity to edaravone or any of the inactive ingredients of this product. Hypersensitivity reactions (redness, wheals, and erythema multiforme) and cases of anaphylaxis (urticaria, decreased blood pressure, and dyspnea) have occurred.
Patients should be monitored carefully for hypersensitivity reactions. If hypersensitivity reactions occur, discontinue RADICAVA ORS, treat per standard of care, and monitor until the condition resolves.
RADICAVA ORS contains sodium bisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown but occurs more frequently in asthmatic people.
The most common adverse reactions (≥10%) reported in RADICAVA® (edaravone)-treated patients and at least 2% more frequently than placebo were contusion (15% vs 9%), gait disturbance (13% vs 9%), and headache (10% vs 6%), respectively. In an open label study, fatigue was also observed in 7.6% of patients receiving RADICAVA ORS.
Based on animal data, RADICAVA ORS may cause fetal harm.
To report suspected adverse reactions or product complaints, contact Mitsubishi Tanabe Pharma America, Inc., at 1-888-292-0058. You may also report suspected adverse reactions to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
RADICAVA ORS® (edaravone) is indicated for the treatment of amyotrophic lateral sclerosis (ALS).
Please see full Prescribing Information also available www.radicavaors.com.
You are leaving this website, hosted by Mitsubishi Tanabe Pharma America.
This link may take you to a website to which our Privacy Policy does not apply.
Mitsubishi Tanabe Pharma America does not control the content of third-party sites.